MA58087B1 - Nouveaux dérivés de méthylquinazolinone - Google Patents

Nouveaux dérivés de méthylquinazolinone

Info

Publication number
MA58087B1
MA58087B1 MA58087A MA58087A MA58087B1 MA 58087 B1 MA58087 B1 MA 58087B1 MA 58087 A MA58087 A MA 58087A MA 58087 A MA58087 A MA 58087A MA 58087 B1 MA58087 B1 MA 58087B1
Authority
MA
Morocco
Prior art keywords
methylquinazolinone
derivatives
new
compound
formula
Prior art date
Application number
MA58087A
Other languages
English (en)
Inventor
Daniel Hunziker
Cosimo Dolente
David Stephen HEWINGS
Daniela Krummenacher
Piergiorgio Francesco Tommaso PETTAZZONI
Juergen Wichmann
Original Assignee
F. Hoffmann-La Roche Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by F. Hoffmann-La Roche Ag filed Critical F. Hoffmann-La Roche Ag
Publication of MA58087B1 publication Critical patent/MA58087B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/46—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with hetero atoms directly attached to the ring nitrogen atom
    • C07D207/48—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Combines (AREA)
  • Harvester Elements (AREA)

Abstract

L'invention concerne un nouveau composé ayant la formule générale (I), ou un sel pharmaceutiquement acceptable de celui-ci. Le composé de formule (I) peut être utilisé en tant que médicament.
MA58087A 2019-12-10 2020-12-08 Nouveaux dérivés de méthylquinazolinone MA58087B1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP19214941 2019-12-10
EP20817377.3A EP4073065B1 (fr) 2019-12-10 2020-12-08 Nouveaux dérivés de methylquinazolinone
PCT/EP2020/084976 WO2021116055A1 (fr) 2019-12-10 2020-12-08 Nouveaux dérivés de méthylquinazolinone

Publications (1)

Publication Number Publication Date
MA58087B1 true MA58087B1 (fr) 2025-04-30

Family

ID=68848113

Family Applications (1)

Application Number Title Priority Date Filing Date
MA58087A MA58087B1 (fr) 2019-12-10 2020-12-08 Nouveaux dérivés de méthylquinazolinone

Country Status (29)

Country Link
US (2) US12116349B2 (fr)
EP (2) EP4483882A3 (fr)
JP (2) JP7108146B2 (fr)
KR (1) KR102836833B1 (fr)
CN (2) CN114787156B (fr)
AR (1) AR122351A1 (fr)
AU (1) AU2020403443B2 (fr)
CL (1) CL2022001529A1 (fr)
CO (1) CO2022008968A2 (fr)
CR (1) CR20220251A (fr)
DK (1) DK4073065T3 (fr)
ES (1) ES3023264T3 (fr)
FI (1) FI4073065T3 (fr)
HR (1) HRP20250418T1 (fr)
HU (1) HUE071148T2 (fr)
IL (2) IL292161B2 (fr)
LT (1) LT4073065T (fr)
MA (1) MA58087B1 (fr)
MX (1) MX2022006783A (fr)
PE (1) PE20221778A1 (fr)
PH (1) PH12022551119A1 (fr)
PL (1) PL4073065T3 (fr)
PT (1) PT4073065T (fr)
RS (1) RS66721B1 (fr)
SI (1) SI4073065T1 (fr)
TW (2) TWI877268B (fr)
UA (1) UA128299C2 (fr)
WO (1) WO2021116055A1 (fr)
ZA (2) ZA202204675B (fr)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FI4073065T3 (fi) 2019-12-10 2025-04-16 Hoffmann La Roche Uusia metyylikinatsolinonijohdannaisia
KR20220112777A (ko) * 2019-12-10 2022-08-11 에프. 호프만-라 로슈 아게 패러독스 파괴제로서의 새로운 braf 억제제
AU2021289163B2 (en) 2020-06-09 2024-05-02 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders
JP2024523839A (ja) 2021-06-08 2024-07-02 シーフォー セラピューティクス， インコーポレイテッド 突然変異体ｂｒａｆを分解する療法薬
EP4351582B1 (fr) * 2021-06-09 2025-10-08 F. Hoffmann-La Roche AG Combinaison d'un inhibiteur particulier de braf (briseur de paradoxe) avec un antagoniste se liant à l'axe pd-1 pour le traitement du cancer
CN117642166A (zh) * 2021-06-09 2024-03-01 中外制药株式会社 用于癌症治疗的组合疗法
TW202313589A (zh) * 2021-06-09 2023-04-01 瑞士商赫孚孟拉羅股份公司 （３ｒ）－ｎ－〔２－氰基－４－氟－３－（－３－甲基－４－側氧－喹唑啉－６－基）氧－苯基〕－３－氟－吡咯啶－１－磺醯胺之新穎固體形式
MX2024000965A (es) 2021-07-27 2024-02-09 Toray Industries Medicamento para el tratamiento y/o prevencion de cancer.
EP4426305A1 (fr) 2021-11-04 2024-09-11 F. Hoffmann-La Roche AG Nouvelle utilisation d'un composé quinazolinone pour le traitement du cancer
TW202409040A (zh) 2022-07-19 2024-03-01 大陸商西藏海思科製藥有限公司 作為激酶抑制劑的喹唑啉酮衍生物的製備及其用途
CN120265291A (zh) 2022-11-18 2025-07-04 豪夫迈·罗氏有限公司 喹唑啉酮化合物的新用途和制剂
WO2024126660A1 (fr) * 2022-12-15 2024-06-20 F. Hoffmann-La Roche Ag Polythérapie pour le traitement du cancer
AR131372A1 (es) * 2022-12-15 2025-03-12 Hoffmann La Roche Procedimiento para la preparación de un derivado de quinazolinona
KR20260032991A (ko) 2023-07-04 2026-03-10 에프. 호프만-라 로슈 아게 (3r)-n-[2-시아노-4-플루오로-3-(3-메틸-4-옥소-퀴나졸린-6-일)옥시-페닐]-3-플루오로-피롤리딘-1-설폰아미드의신규 고체 형태
WO2025108405A1 (fr) * 2023-11-22 2025-05-30 西藏海思科制药有限公司 Préparation d'un dérivé de quinazolinone destiné à être utilisé en tant qu'inhibiteur de kinase, et son utilisation
TW202545530A (zh) * 2024-01-17 2025-12-01 大陸商海思科醫藥集團股份有限公司 含ｂｒａｆ抑制劑的藥物組合物及其在醫藥上的應用
WO2026037755A1 (fr) 2024-08-13 2026-02-19 F. Hoffmann-La Roche Ag Nouveaux dérivés de méthylquinazolinone
WO2026046946A1 (fr) 2024-08-28 2026-03-05 F. Hoffmann-La Roche Ag Nouvelles formes solides de (3r)-n-[2-cyano-4-fluoro-3-(3-méthyl-4-oxo-quinazolin-6-yl)oxy-phényl]-3-fluoro-pyrrolidine-1-sulfonamide

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP4429085B2 (ja) 2004-06-08 2010-03-10 有限会社コンペックス 茸栽培用殺菌菌床組成物の製造法及び茸栽培法
GB0525068D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
GB0525069D0 (en) 2005-12-08 2006-01-18 Novartis Ag Organic compounds
US20100190777A1 (en) 2007-07-17 2010-07-29 Plexxikon Inc. Compounds and methods for kinase modulation, and indications therefor
PL2947072T3 (pl) 2008-03-17 2017-05-31 Ambit Biosciences Corporation 1-(3-(6,7-dimetoksychinazolin-4-yloksy)fenylo)-3-(5-(1,1,1-trifluoro-2-metylopropan-2-ylo)izoksazol-3-ilo)mocznik jako modulator kinazy RAF w leczeniu chorób nowotworowych
US8349852B2 (en) 2009-01-13 2013-01-08 Novartis Ag Quinazolinone derivatives useful as vanilloid antagonists
TW201041888A (en) 2009-05-06 2010-12-01 Plexxikon Inc Compounds and methods for kinase modulation, and indications therefor
WO2012118492A1 (fr) * 2011-03-01 2012-09-07 Array Biopharma Inc. Sulfonamides hétérocycliques en tant qu'inhibiteurs de raf
AR091876A1 (es) 2012-07-26 2015-03-04 Novartis Ag Combinaciones farmaceuticas para el tratamiento de enfermedades proliferativas
AU2013318283A1 (en) 2012-09-19 2015-03-05 Novartis Ag Dihydropyrrolidino-pyrimidines as kinase inhibitors
AU2014274093B2 (en) 2013-05-30 2018-11-08 Plexxikon Inc. Compounds for kinase modulation, and indications therefor
CN113893253A (zh) 2015-05-22 2022-01-07 普莱希科公司 用于治疗braf-v600相关的疾病的plx-8394或plx-7904
PL3359541T3 (pl) 2015-10-09 2021-01-11 AbbVie Overseas S.à r.l. N-SULFONYLOWANE PIRAZOLO[3,4-b]PIRYDYNO-6-KARBOKSAMIDY I SPOSÓB ZASTOSOWANIA
RU2687107C1 (ru) 2018-06-18 2019-05-07 федеральное государственное автономное образовательное учреждение высшего образования "Московский физико-технический институт (государственный университет)" Ингибитор braf киназы n-(3-(5-(4-хлорофенил)-1h-пиразоло[3,4-b]пиридин-3-карбонил)-2,4-дифторофенил) пропан-1-сульфонамид
JP7539892B2 (ja) 2019-01-03 2024-08-26 ジェネンテック， インコーポレイテッド 癌疾患の処置のためのエンドリボヌクレアーゼのイノシトール要求酵素ｉ（ｉｒｅｉアルファ）の阻害剤としてのピリド－ピリミジノン化合物及びプテリジノン化合物
TWI817018B (zh) * 2019-06-28 2023-10-01 美商艾瑞生藥股份有限公司 用於治療ｂｒａｆ相關的疾病和失調症之化合物
KR20220112777A (ko) 2019-12-10 2022-08-11 에프. 호프만-라 로슈 아게 패러독스 파괴제로서의 새로운 braf 억제제
FI4073065T3 (fi) 2019-12-10 2025-04-16 Hoffmann La Roche Uusia metyylikinatsolinonijohdannaisia
AU2021289163B2 (en) 2020-06-09 2024-05-02 Array Biopharma Inc. 4-oxo-3,4-dihydroquinazolinon compounds for the treatment of BRAF-associated diseases and disorders
WO2022129259A1 (fr) 2020-12-18 2022-06-23 F. Hoffmann-La Roche Ag Nouveaux dérivés de quinazolinone
EP4263541A1 (fr) 2020-12-18 2023-10-25 F. Hoffmann-La Roche AG Nouveaux dérivés d'aryl-pyrido-pyrimidin-one
JP2024523839A (ja) 2021-06-08 2024-07-02 シーフォー セラピューティクス， インコーポレイテッド 突然変異体ｂｒａｆを分解する療法薬
JP2024545073A (ja) 2021-12-08 2024-12-05 アレイ バイオファーマ インコーポレイテッド Ｎ－（２－クロロ－３－（（５－クロロ－３－メチル－４－オキソ－３，４－ジヒドロキナゾリン－６－イル）アミノ）－４－フルオロフェニル）－３－フルオロアゼチジン－１－スルホンアミドの結晶形態

Also Published As

Publication number Publication date
EP4073065A1 (fr) 2022-10-19
ES3023264T3 (en) 2025-05-30
US20240174621A1 (en) 2024-05-30
JP7802514B2 (ja) 2026-01-20
EP4483882A3 (fr) 2025-03-05
PH12022551119A1 (en) 2023-08-23
KR102836833B1 (ko) 2025-07-22
IL292161B1 (en) 2024-12-01
BR112022011123A2 (pt) 2022-08-23
EP4483882A2 (fr) 2025-01-01
FI4073065T3 (fi) 2025-04-16
TWI908405B (zh) 2025-12-11
CA3162883A1 (fr) 2021-06-17
LT4073065T (lt) 2025-04-25
PL4073065T3 (pl) 2025-05-19
JP2022124458A (ja) 2022-08-25
WO2021116055A1 (fr) 2021-06-17
JP2022531609A (ja) 2022-07-07
MX2022006783A (es) 2022-07-11
US12116349B2 (en) 2024-10-15
UA128299C2 (uk) 2024-05-29
US20220298119A1 (en) 2022-09-22
AU2020403443B2 (en) 2023-02-23
HRP20250418T1 (hr) 2025-06-06
CN114787156B (zh) 2024-07-26
TWI877268B (zh) 2025-03-21
JP7108146B2 (ja) 2022-07-27
AU2020403443A1 (en) 2022-05-12
CR20220251A (es) 2022-07-11
ZA202204675B (en) 2022-12-21
TW202136245A (zh) 2021-10-01
RS66721B1 (sr) 2025-05-30
TW202504895A (zh) 2025-02-01
EP4073065B1 (fr) 2025-02-19
IL316473A (en) 2024-12-01
SI4073065T1 (sl) 2025-06-30
HUE071148T2 (hu) 2025-08-28
IL292161A (en) 2022-06-01
CL2022001529A1 (es) 2023-02-10
ZA202206923B (en) 2024-10-30
CO2022008968A2 (es) 2022-07-19
CN118791472A (zh) 2024-10-18
AR122351A1 (es) 2022-09-07
CN114787156A (zh) 2022-07-22
IL292161B2 (en) 2025-04-01
NZ787393A (en) 2025-07-25
PE20221778A1 (es) 2022-11-16
PT4073065T (pt) 2025-04-15
DK4073065T3 (da) 2025-04-22
KR20220110554A (ko) 2022-08-08

Similar Documents

Publication Publication Date Title
MA52948B1 (fr) Composés
MA46337A (fr) Composé de pyridine
MX2022006783A (es) Nuevos derivados de metilquinazolinona.
CR20200588A (es) Compuestos novedosos
MA37866B1 (fr) Dérivés de type aza-indazole ou diaza-indazole pour le traitement de la douleur
EA202092253A1 (ru) Замещенные производные имидазолидин-2-она в качестве ингибиторов prmt5
EA201892300A1 (ru) Макроциклические ингибиторы mcl1 для лечения рака
MA51431B1 (fr) Dérivés d'oxy-fluoropipéridine utilisés en tant qu'inhibiteur de kinase
MA38472A1 (fr) Composé peptidique
MA45782B1 (fr) Modulateurs du récepteur de cxcr7 pipéridine
MA46101B1 (fr) Modulateurs allostériques positifs du récepteur muscarinique m1
MA41338A (fr) Composés de pyrazine pour le traitement de maladies infectieuses
MA38390B1 (fr) Composés tétrahydropyrrolothiazines
MA42341B2 (fr) Inhibiteur de protéine kinase, son procédé de préparation et son utilisation médicale
MA38323A1 (fr) Dérivés pyrimidone et leur utilisation dans le traitement, l'amélioration ou la prévention d'une maladie virale
MA42339A1 (fr) Modulateurs du récepteur farnésoïde x
MA39335B1 (fr) Inhibiteurs mgat2 de dihydropyridinone à substitution tétrazolone
MA39983A (fr) Dérivés de carboxamide
JOP20210039B1 (ar) مركبات بيريدين 6،2 - ديامينو
MA38865A1 (fr) Formulation comprenant un agent hypolipidémiant
MX2020013297A (es) Compuestos para el tratamiento o la prevencion de enfermedades hepaticas.
MA39315A1 (fr) Dérivés de pyridazine à utiliser dans la prévention ou le traitement d'un trouble ataxique
MX2020004930A (es) Compuestos de biarilo sustituido novedosos como inhibidores de indolamina 2,3-dioxigenasa (ido).
SA522441650B1 (ar) مثبطات فوسفوينوسيتيد 3-كيناز الموضعية
MA46039B1 (fr) Dérivé de triazolopyrazinone utile en tant qu'inhibiteur de pde1 humain